Combined use of ciprofloxacin and sucralfate

A. D. Van Slooten, David E. Nix, J. H. Wilton, J. H. Love, J. M. Spivey, H. R. Goldstein

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

The effect of sucralfate on the bioavailability of ciprofloxacin hydrochloride was assessed in 12 healthy male volunteers. The study was a four-period crossover design where subjects were randomized to one of four treatment sequences at entry. Treatments A, B, and C included sucralfate 2 g q12h for five doses. For treatment A, the fifth dose of sucralfate was administered concurrendy with ciprofloxacin 750 mg. For treatment B, 750 mg of ciprofloxacin was administered two hours before the fifth dose of sucralfate. Treatment C consisted of ciprofloxacin 750 mg six hours before the fifth dose of sucralfate. A 750-mg dose of ciprofloxacin was administered alone for treatment D. Blood and urine samples were collected at predetermined time intervals for 24 hours. Ciprofloxacin concentrations were determined by HPLC. The area under the concentration versus time curve from zero to infinity and the urinary recovery of ciprofloxacin were used for determining relative bioavailability. Concurrent administration of ciprofloxacin and sucralfate (treatment A) resulted in a significant decrease (p < 0.05) in ciprofloxacin absorption. The relative bioavailabilities for treatments A, B, and C were 0.0429 ± 0.0202, 0.829 + 0.21, and 0.965 + 0.32, respectively, relative to ciprofloxacin alone. In normal volunteers, ciprofloxacin may be administered between two and six hours before sucralfate, allowing sufficient time for ciprofloxacin absorption prior to the sucralfate dose and thereby minimizing the chance of a significant interaction. In patients with decreased gastric emptying the interaction may be more difficult to avoid.

Original languageEnglish (US)
Pages (from-to)578-582
Number of pages5
JournalDICP, Annals of Pharmacotherapy
Volume25
Issue number6
StatePublished - 1991
Externally publishedYes

Fingerprint

Sucralfate
Ciprofloxacin
Biological Availability
Therapeutics
Healthy Volunteers
Gastric Emptying
Cross-Over Studies

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Van Slooten, A. D., Nix, D. E., Wilton, J. H., Love, J. H., Spivey, J. M., & Goldstein, H. R. (1991). Combined use of ciprofloxacin and sucralfate. DICP, Annals of Pharmacotherapy, 25(6), 578-582.

Combined use of ciprofloxacin and sucralfate. / Van Slooten, A. D.; Nix, David E.; Wilton, J. H.; Love, J. H.; Spivey, J. M.; Goldstein, H. R.

In: DICP, Annals of Pharmacotherapy, Vol. 25, No. 6, 1991, p. 578-582.

Research output: Contribution to journalArticle

Van Slooten, AD, Nix, DE, Wilton, JH, Love, JH, Spivey, JM & Goldstein, HR 1991, 'Combined use of ciprofloxacin and sucralfate', DICP, Annals of Pharmacotherapy, vol. 25, no. 6, pp. 578-582.
Van Slooten AD, Nix DE, Wilton JH, Love JH, Spivey JM, Goldstein HR. Combined use of ciprofloxacin and sucralfate. DICP, Annals of Pharmacotherapy. 1991;25(6):578-582.
Van Slooten, A. D. ; Nix, David E. ; Wilton, J. H. ; Love, J. H. ; Spivey, J. M. ; Goldstein, H. R. / Combined use of ciprofloxacin and sucralfate. In: DICP, Annals of Pharmacotherapy. 1991 ; Vol. 25, No. 6. pp. 578-582.
@article{c2df616b665b4ef8ab92d546fba8d1d8,
title = "Combined use of ciprofloxacin and sucralfate",
abstract = "The effect of sucralfate on the bioavailability of ciprofloxacin hydrochloride was assessed in 12 healthy male volunteers. The study was a four-period crossover design where subjects were randomized to one of four treatment sequences at entry. Treatments A, B, and C included sucralfate 2 g q12h for five doses. For treatment A, the fifth dose of sucralfate was administered concurrendy with ciprofloxacin 750 mg. For treatment B, 750 mg of ciprofloxacin was administered two hours before the fifth dose of sucralfate. Treatment C consisted of ciprofloxacin 750 mg six hours before the fifth dose of sucralfate. A 750-mg dose of ciprofloxacin was administered alone for treatment D. Blood and urine samples were collected at predetermined time intervals for 24 hours. Ciprofloxacin concentrations were determined by HPLC. The area under the concentration versus time curve from zero to infinity and the urinary recovery of ciprofloxacin were used for determining relative bioavailability. Concurrent administration of ciprofloxacin and sucralfate (treatment A) resulted in a significant decrease (p < 0.05) in ciprofloxacin absorption. The relative bioavailabilities for treatments A, B, and C were 0.0429 ± 0.0202, 0.829 + 0.21, and 0.965 + 0.32, respectively, relative to ciprofloxacin alone. In normal volunteers, ciprofloxacin may be administered between two and six hours before sucralfate, allowing sufficient time for ciprofloxacin absorption prior to the sucralfate dose and thereby minimizing the chance of a significant interaction. In patients with decreased gastric emptying the interaction may be more difficult to avoid.",
author = "{Van Slooten}, {A. D.} and Nix, {David E.} and Wilton, {J. H.} and Love, {J. H.} and Spivey, {J. M.} and Goldstein, {H. R.}",
year = "1991",
language = "English (US)",
volume = "25",
pages = "578--582",
journal = "Annals of Pharmacotherapy",
issn = "1060-0280",
publisher = "Harvey Whitney Books Company",
number = "6",

}

TY - JOUR

T1 - Combined use of ciprofloxacin and sucralfate

AU - Van Slooten, A. D.

AU - Nix, David E.

AU - Wilton, J. H.

AU - Love, J. H.

AU - Spivey, J. M.

AU - Goldstein, H. R.

PY - 1991

Y1 - 1991

N2 - The effect of sucralfate on the bioavailability of ciprofloxacin hydrochloride was assessed in 12 healthy male volunteers. The study was a four-period crossover design where subjects were randomized to one of four treatment sequences at entry. Treatments A, B, and C included sucralfate 2 g q12h for five doses. For treatment A, the fifth dose of sucralfate was administered concurrendy with ciprofloxacin 750 mg. For treatment B, 750 mg of ciprofloxacin was administered two hours before the fifth dose of sucralfate. Treatment C consisted of ciprofloxacin 750 mg six hours before the fifth dose of sucralfate. A 750-mg dose of ciprofloxacin was administered alone for treatment D. Blood and urine samples were collected at predetermined time intervals for 24 hours. Ciprofloxacin concentrations were determined by HPLC. The area under the concentration versus time curve from zero to infinity and the urinary recovery of ciprofloxacin were used for determining relative bioavailability. Concurrent administration of ciprofloxacin and sucralfate (treatment A) resulted in a significant decrease (p < 0.05) in ciprofloxacin absorption. The relative bioavailabilities for treatments A, B, and C were 0.0429 ± 0.0202, 0.829 + 0.21, and 0.965 + 0.32, respectively, relative to ciprofloxacin alone. In normal volunteers, ciprofloxacin may be administered between two and six hours before sucralfate, allowing sufficient time for ciprofloxacin absorption prior to the sucralfate dose and thereby minimizing the chance of a significant interaction. In patients with decreased gastric emptying the interaction may be more difficult to avoid.

AB - The effect of sucralfate on the bioavailability of ciprofloxacin hydrochloride was assessed in 12 healthy male volunteers. The study was a four-period crossover design where subjects were randomized to one of four treatment sequences at entry. Treatments A, B, and C included sucralfate 2 g q12h for five doses. For treatment A, the fifth dose of sucralfate was administered concurrendy with ciprofloxacin 750 mg. For treatment B, 750 mg of ciprofloxacin was administered two hours before the fifth dose of sucralfate. Treatment C consisted of ciprofloxacin 750 mg six hours before the fifth dose of sucralfate. A 750-mg dose of ciprofloxacin was administered alone for treatment D. Blood and urine samples were collected at predetermined time intervals for 24 hours. Ciprofloxacin concentrations were determined by HPLC. The area under the concentration versus time curve from zero to infinity and the urinary recovery of ciprofloxacin were used for determining relative bioavailability. Concurrent administration of ciprofloxacin and sucralfate (treatment A) resulted in a significant decrease (p < 0.05) in ciprofloxacin absorption. The relative bioavailabilities for treatments A, B, and C were 0.0429 ± 0.0202, 0.829 + 0.21, and 0.965 + 0.32, respectively, relative to ciprofloxacin alone. In normal volunteers, ciprofloxacin may be administered between two and six hours before sucralfate, allowing sufficient time for ciprofloxacin absorption prior to the sucralfate dose and thereby minimizing the chance of a significant interaction. In patients with decreased gastric emptying the interaction may be more difficult to avoid.

UR - http://www.scopus.com/inward/record.url?scp=0025737409&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025737409&partnerID=8YFLogxK

M3 - Article

VL - 25

SP - 578

EP - 582

JO - Annals of Pharmacotherapy

JF - Annals of Pharmacotherapy

SN - 1060-0280

IS - 6

ER -